A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

NCT05751512 | Unknown Phase 3

• 1 other identifier: MRG003-010
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.

Conditions

Squamous Cell Carcinoma of the Head and Neck

Keywords

MRG003; Antibody Drug Conjugate (ADC); SCCHN

Outcome Measures

Primary Outcomes (1)

• Overall Survival (OS)

  OS is defined as the duration from the start of treatment to death of any cause.

  Baseline to study completion (up to 24 months)

Secondary Outcomes (8)

• Progression Free Survival (PFS)

  Baseline to study completion (up to 24 months)

• Objective Response Rate (ORR)

  Baseline to study completion (up to 24 months)

• Disease Control Rate (DCR)

  Baseline to study completion (up to 24 months)

• Duration of Response (DOR)

  Baseline to study completion (up to 24 months)

• Treatment Related Adverse Events (TRAE)

  Baseline to 30 days after the last dose of study treatment

Study Arms (2)

MRG003

EXPERIMENTAL

MRG003 will be administrated via intravenous infusion at 2.3 mg/kg once on Day 1 of every 3 weeks (21-day cycle).

Drug: MRG003

cetuximab/ methotrexate

ACTIVE COMPARATOR

cetuximab (400 mg/m2 for the first week and 250 mg/m2 for subsequent weeks, QW) or methotrexate (40 mg/m2, IV, QW)

Drug: Cetuximab injection; Drug: Methotrexate Injection

Interventions

MRG003 DRUG

Administered intravenously

MRG003

Cetuximab injection DRUG

Administered intravenously

cetuximab/ methotrexate

Methotrexate Injection DRUG

Administered intravenously

cetuximab/ methotrexate

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- 1. Understands and provides written informed consent and willing to follow the requirements specified in protocol.
• \. Age: ≥18 years and ≤75 years. 3. Life expectancy: ≥3 months. 4. Must have histologically or cytologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (including oral cavity, oropharynx, hypopharynx, larynx) who had previously failed PD-1 (L1) inhibitors and platinum-based therapy (in combination or sequential). Prior therapies should be no more than 2 lines.
• Note: If disease progression occurred during neoadjuvant/adjuvant treatment or concurrent radiotherapy, or within 6 months after treatment discontinuation, the anti-tumor therapies (including platinum-based chemotherapy, anti-EGFR monoclonal antibody, PD-1 (L1) inhibitors, etc.) during neoadjuvant/adjuvant treatment or concurrent radiotherapy is counted as one line of prior treatment. Discontinuation or dose reduction of one drug, or change of platinum- or fluorouracil-based agents or PD-1 (L1) inhibitors without disease progression is considered as the same line of treatment.
• \. Must have at least one measurable lesion per RECIST v1.1. Previously irradiated lesion cannot be considered as target unless there is documented progression three months after the last treatment of radiotherapy.
• \. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 1) with no deterioration within 2 weeks prior to enrollment.
• \. Adequate bone marrow function, defined as meeting all of the following criteria and having no transfusion therapy within 3 weeks (21 days) or growth factors (G-CSF, EPO, etc.) support within 2 weeks (14 days) prior to dosing:
• Hemoglobin (Hb) ≥ 9.0 g/dL (90 g/L)
• Absolute neutrophil count (ANC) ≥ 1,500/mcL (1.5 × 109/L)
• Total platelet count (PLT) ≥ 100,000/mcL (100 × 109/L) 8. Adequate hepatic function, defined as all of the following:
• Total bilirubin (TBIL) ≤ 1.5×ULN;
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN if no liver metastasis; ALT or AST ≤ 3.0×ULN in the presence of liver metastasis;
• Alkaline phosphatase (ALP) ≤ 1.5×ULN; ≤ 2×ULN in the presence of liver metastasis;
• Serum albumin ≥ 30 g/L 9. Coagulation: International Normalized Ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (APTT) ≤ 1.5×ULN (unless patient is receiving anticoagulant therapy whose anticoagulant level should be within the therapeutic range). The laboratory parameters should be closely monitored by investigator if the patient is on anticoagulation therapy.
• \. Adequate renal function, defined as Creatinine ≤ 1.5×ULN or creatinine clearance rate (Ccr) ≥ 50 mL/min if Creatinine \> 1.5×ULN (Creatinine clearance is calculated using the modified Cockcroft-Gault equation. Creatinine clearance can be calculated as Ccr = \[(140-age) × body weight (kg) × (0.85 for women only)\]/(72 × serum creatinine) if no local guidelines are available (without significant electrolyte imbalance that is not easily corrected).
• \. Baseline Left Ventricular Ejection Fraction (LVEF) ≥ 50% measured by multiple-gated acquisition (MUGA) or echocardiogram (ECHO).

You may not qualify if:

• \. Grade ≥2 peripheral neuropathy per CTCAE v5.0. 2. Is expected to require surgery or any other form of systemic or local anti-tumor therapy during the study, including maintenance therapy or radiotherapy (including palliative therapy, except for palliative therapy for non-target lesions) for SCCHN.
• \. Received systemic chemotherapy within 3 weeks, small molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer), biological anti-tumor therapy, macromolecule targeted therapy or immunotherapy within 4 weeks before the first dose of study treatment, or major surgery (except for minor surgery within 2 weeks and fully recovered); radiotherapy (except radiotherapy for CNS, wash-out period ≥ 28 days is required) within 14 days before the first dose of study treatment.
• \. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with brain metastases may participate provided they are treated and stable, and do not have the following:
• Progressive or new neurological deficits, seizures, evidence of increased intracranial pressure, vomiting, or headache;
• Evidence of enlarging brain metastases by MRI at least 4 weeks prior to the first dose and corticosteroids is required for at least 14 days prior to study drug treatment.
• \. Residual toxicities (except alopecia, fatigue, and Grade 2 hypothyroidism) due to prior anti-tumor therapy (including immunotherapy, targeted therapy, chemotherapy or radiotherapy) or ≥ Grade 1 (CTCAE v5.0) clinically significant laboratory abnormality.
• \. Uncontrolled or poorly controlled cardiac dysfunction, including congestive heart failure (CHF) ≥ Grade 2 (CTCAE v5.0 or New York Heart Association classification), history of myocardial infarction, unstable angina pectoris, ventricular tachycardia or torsades de pointes, or cardiac rhythm loss requiring treatment within 6 months prior to enrollment, for example, QTcF \> 450 ms in men, QTcF \> 470 ms in women, in presence of complete left bundle branch block or third-degree atrioventricular block. QTcF = QT/ (RR\^0.33).
• \. Pulmonary embolism or deep venous thrombosis (except for thrombosis caused by infusion port or PICC line) within 3 months prior to the first dose of study drug.
• \. Known history of malignancy (except for patients with cutaneous basal cell carcinoma, superficial bladder carcinoma, cutaneous squamous cell carcinoma, carcinoma in situ, or papillary thyroid carcinoma who have undergone curative surgery) unless the patient has received potentially curative therapy and has not had disease recurrence within 5 years prior to study treatment.
• Note: The 5-year recurrence-free time requirement does not apply to SCCHN patients enrolled in this study.
• \. Any serious or uncontrolled systemic disease, including uncontrolled or poorly controlled hypertension (e.g., systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg), diabetes mellitus (glycosylated hemoglobin (HbA1c) \> 8%), etc.
• \. Patients with active bleeding, history of coagulopathy, or receiving coumarin anticoagulant therapy.
• \. Known allergic reactions to any component or excipients of MRG003 (citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80) or known allergic reactions to other anti-EGFR agents (including investigational drug) or to other monoclonal antibodies ≥ Grade 3.
• \. Known active hepatitis B or C. Active hepatitis B is defined as known positive HBsAg result and HBV DNA ≥ 500 IU/mL. Active hepatitis C is defined as known positive hepatitis C antibody result and known quantitative hepatitis C virus (HCV) RNA results greater than the lower limit of detection. Presence of other serious liver diseases, including chronic autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis, alcoholic liver disease, or nonalcoholic steatohepatitis (NASH).
• \. Concurrent, serious, uncontrolled infection or known infection with human immunodeficiency virus (HIV) (HIV antibody positive), or diagnosis of acquired immunodeficiency syndrome (AIDS); or uncontrolled autoimmune disease; or previous allogeneic tissue/organ transplantation, stem cell or bone marrow transplantation, or previous solid organ transplantation.

Sponsors & Collaborators

• Shanghai Miracogen Inc.: lead

Study Sites (1)

Shanghai East Hospital

Shanghai, Shanghai Municipality, 200123, China

Location

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

Cetuximab; Methotrexate

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Aminopterin; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Ye Guo, PhD

  Shanghai East Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Program Director

CONTACT

86-21-61637960; clinicaltrials@miracogen.com.cn

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2023
• First Posted: March 2, 2023
• Study Start: March 1, 2023
• Primary Completion: August 1, 2025
• Study Completion: December 1, 2025
• Last Updated: March 2, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)